Clinical Trials Arena on MSN
AbbVie could take BITE of Tecvayli market share on Phase III MM win
If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of ...
CARLISLE, Pa. — A Cumberland County woman, who, earlier this year, was given months to live, is now thriving due to a newly-approved, cutting-edge cancer treatment. Wanda Stouffer, 77, was diagnosed ...
Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings. Despite advances in solid tumor treatments, including small cell ...
Hosted on MSN
Home-based monitoring could transform care for patients receiving T-cell redirecting therapies
Supercharging patients' immune system T-cell redirecting therapies, including CAR-T and bispecific T cell engagers (BiTEs), are a type of immunotherapy that supercharges the patient's immune system to ...
Arlo-cel uses autologous T-cell collection, ex vivo CAR engineering, lymphodepletion, and single infusion, necessitating infrastructure for manufacturing logistics and post-infusion monitoring. Safety ...
Additionally, Intermountain Health St. Joseph Hospital in Denver, Color., will soon offer BiTE Therapy. Since the new locations began administering the therapy, it is estimated to have saved patients ...
Sarah Hudgens is a content pro with over 15 years of experience writing and editing copy for a wide range of industry verticals and channels. Gagandeep Brar, MD, is a board-certified hematologist and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results